Daily Pirfenidone doses helpful for treating Idiopathic pulmonary fibrosis

According to researchers from Japan, a daily dose of Pirfenidone is effective to treat individuals afflicted with idiopathic pulmonary fibrosis.

As per the Phase III, double-blind, placebo-controlled clinical trial, daily doses of this drug can prove to be an effective option for slowing down the progression of idiopathic pulmonary fibrosis and reducing the loss of lung capacity.

From News-Medical.Net:

"The most common treatment for IPF is anti-inflammatory agents such as steroids," said lead researcher Takashi Ogura, M.D., of Kanagawa Cardiovascular and Respiratory Center in Yokohama, Japan. "However our study confirmed that pirfenidone, the main action of which is thought to be antifibrotic, achieved a therapeutic effect on IPF. I expect that our study will serve as a guide to develop a new therapy for IPF in the future."

The researchers recruited a total of 275 Japanese patients with mild to moderate IPF and randomized them to a high dose pirfenidone (1,800 mg/day) group, a low dose pirfenidone group (1,200 mg/day) and a placebo group. They measured lung capacity (vital capacity or VC) and progression-free survival, defined as a period without death or a greater than 10 percent decrease in VC, to determine the effectiveness of the regimens.

At the end of one year, they found that patients who had been randomized to the high dose regimen had significantly lower loss of VC than the placebo group. Furthermore, pirfenidone slowed the overall deterioration of IPF compared to the placebo.

"Taken altogether, our study demonstrated positive clinical effects of pirfenidone that suppresses the progress of IPF and potentially contributes to improving the outcomes of patients with IPF," said Dr. Ogura.

The trial results were presented at the American Thoracic Society's International Conference in Toronto.